Journal article
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II) The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial
S Siva, M Bressel, T Mai, H Le, S Vinod, H de Silva, S Macdonald, M Skala, N Hardcastle, A Rezo, D Pryor, S Gill, B Higgs, K Wagenfuehr, R Montgomery, R Awad, B Chesson, T Eade, W Wong, G Sasso Show all
JAMA Oncology | Published : 2021
Abstract
IMPORTANCE Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases. OBJECTIVE To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients with pulmonary oligometastases. DESIGN, SETTING, AND PARTICIPANTS This multicenter, unblinded, phase 2 randomized clinical trial of 90 patients across 13 centers in Australia and New Zealand enrolled patients with 1 to 3 lung oligometastases less than or equal to 5 cm from any nonhematologic malignant tumors located away from the central airways, Eastern Cooperative Oncology Group performance st..
View full abstractGrants
Awarded by Varian Medical Systems
Funding Acknowledgements
This study was funded by the Priority-Driven Collaborative Cancer Research Scheme APP1082399 from Cancer Australia and by grant APP2116004 from the Auckland Medical Research Foundation. The translational substudy was supported by Varian Medical Systems (Palo Alto, California) and the Victorian Cancer Center Immunotherapy program. Dr Siva was supported by a National Health and Medical Research Council fellowship (APP1122347) and a Cancer Council Victoria Colebatch Fellowship. This study was sponsored by the Trans Tasman Radiation Oncology Group.